We are live on ! Find out more
BSPM

Biostar Pharmaceuticals
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

8 hedge funds and large institutions have $251K invested in Biostar Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

4.57% less ownership

Funds ownership: 7.13% → 2.55% (-4.6%)

70% less capital inflows, than outflows

Capital inflows: $181K | Capital outflows: $604K

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BSPM Hedge Fund Activity: Q3 2016 in Review

8 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals (BSPM) for Q3 2016, worth a combined $251K — down 64% from $697K a quarter earlier.

Fund positioning in BSPM was balanced in Q3 2016: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Acrospire Investment Management, adding an estimated $76.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $468K sold.

  • 8 institutional investors held Biostar Pharmaceuticals (BSPM) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $251K of Biostar Pharmaceuticals stock for Q3 2016, down 64% quarter-over-quarter.
  • 3 funds opened new Biostar Pharmaceuticals positions in Q3 2016 and 3 closed out, a net change of 0 holders.
  • The largest Biostar Pharmaceuticals buyer in Q3 2016 was Acrospire Investment Management, an estimated $76.6K added.
  • The largest Biostar Pharmaceuticals seller in Q3 2016 was Renaissance Technologies, an estimated $468K sold.

Based on aggregated 13F filings for Q3 2016.